Elotuzumab
Elotuzumab
Definition
A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.
Also known as BMS 901608, BMS-901608, BMS901608, ELOTUZUMAB, Empliciti, HuLuc-63, HuLuc63, PDL 063, PDL-063, PDL063 — per NCIT
Also identified as
- ATC L01FX08 per RXNORM
- NCIT NCIT:C66982 per NCIT
- SCTID 715660001 per RXNORM
- SCTID 781350003 per RXNORM
- UNII 1351PE5UGS per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Multiple myeloma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Lymphoid system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.